A blockbuster brand doesn’t sustain itself. Behind every successful product lifecycle — across new indications, evolving patient populations, and an increasingly crowded competitive landscape — there’s an insights engine quietly doing the hard work.
HawkPartners joined colleagues from Sanofi and Regeneron to reflect on more than a decade of strategic insights work behind DUPIXENT, one of the most consequential growth stories in recent biopharma. What emerged was a set of lessons that extends beyond any single indication: when a brand expands over time, the insights mandate expands with it. Building and sustaining leadership requires more than strong launch fundamentals; it requires a disciplined understanding of how markets evolve, how decisions are made within each specialty, and where the next source of growth will come from.
1. Launch is just the beginning of the insights challenge
For DUPIXENT, the early commercial challenge was not simply awareness; it was helping the market build conviction in a therapy that asked clinicians to reassess established treatment expectations. That is where insights work plays its most strategic role at launch: clarifying what will give prescribers confidence, what evidence changes behavior, and which barriers are structural versus perceptual. The teams that build durable brand equity are usually the ones that treat launch as the start of a longer learning agenda, not the end of one.
2. Each new indication is a new audience — and a new learning opportunity
One of the most important realities of portfolio expansion is that a new indication rarely behaves like an extension of the last one. In DUPIXENT’s case, the science may create continuity, but the commercial context still resets: different specialists, different treatment algorithms, different patient and caregiver dynamics, and different thresholds for action. That is why the most effective teams are deliberate about what they carry forward, what they revalidate, and where they need new learning to avoid overgeneralizing from prior success.
3. Brand consistency and indication-specific messaging are not in conflict
As brands scale across indications, one of the central strategic questions becomes how to maintain coherence without flattening what matters at the specialty level. DUPIXENT shows why that tension is best managed through clear brand architecture: a consistent core that signals continuity, paired with indication-level messaging that reflects how each market defines value. Done well, that approach strengthens the masterbrand while giving each audience a reason to see the brand as relevant to its own clinical reality.
“Before you can differentiate, you have to make sure the category itself is real in the minds of the people you’re trying to reach.”
4. Competitive maturity demands a different kind of insight work
As category dynamics mature, the role of insights becomes more discriminating. The questions are less about broad positioning and more about where choice can still be influenced: which segments remain movable, which competitor narratives are gaining traction, where assumptions have hardened, and what evidence or messaging can still create separation. At that stage, the most valuable research is not descriptive for its own sake; it helps leadership teams make sharper decisions in a market where the margin for undifferentiated thinking is much smaller.
5. Enduring partnerships compound in value over time
Durable brands also reveal the strategic value of enduring partnerships. Over time, continuity creates more than familiarity; it creates accumulated judgment about what the organization has learned, which questions are actually decision-critical, and how the brand’s context has changed from one phase of growth to the next. That depth of perspective allows external partners to contribute at a higher level — not as episodic research providers, but as thought partners who can connect the brand’s history to its next set of choices.
The brands that lead over time are usually the ones that keep learning with the market, stay rigorous about where growth will come from next, and build the partnerships that help turn insight into sustained advantage.